Skip to main content
Top
Published in: European Journal of Medical Research 1/2012

Open Access 01-12-2012 | Research

Reversal of cerebral radiation necrosis with bevacizumab treatment in 17 Chinese patients

Authors: Yang Wang, Li Pan, Xiaofang Sheng, Yin Mao, Yu Yao, Enmin Wang, Nan Zhang, Jiazhong Dai

Published in: European Journal of Medical Research | Issue 1/2012

Login to get access

Abstract

Background

Bevacizumab has been suggested as a new treatment modality for cerebral radiation necrosis due to its ability to block the effects of vascular endothelial growth factor (VEGF) in leakage-prone capillaries, though its use still remains controversial in clinical practice.

Methods

The use of bevacizumab in 17 patients with symptomatic cerebral radiation necrosis poorly controlled with dexamethasone steroid treatments was examined between March 2010 and January 2012. Bevacizumab therapy was administered for a minimum of two cycles (7.5 mg/kg, at two-week interval) with a median of four bevacizumab injections. Changes in bi-dimensional measurements of the largest radiation necrosis lesions were observed by gadolinium-enhanced and T2-weighted magnetic resonance imaging (MRI). Additionally, dexamethasone dosage, Karnofsky performance status (KPS), adverse event occurrence and associated clinical outcomes were recorded for each patient.

Results

MRI analysis revealed that the average reduction was 54.9% and 48.4% in post-gadolinium and T2-weighted sequence analysis, respectively. Significant clinical neurological improvements were expressed in 10 patients according to KPS values. Dexamethasone reduction was achieved four weeks after initiation of bevacizumab in all patients, with four patients successfully discontinuing dexamethasone treatment. Mild to moderate bevacizumab-related adverse events, such as fatigue, proteinuria and hypertension were observed in three patients. Upon follow-up at 4 to 12 months, 10 patients showed clinical improvement, and 7 patient deaths occurred from tumor progression (5 patients), recurrent necrosis (1 patient), and uncontrolled necrosis-induced edema (1 patient).

Conclusions

These findings suggest bevacizumab as a promising treatment for cerebral radiation necrosis induced by common radiation therapies, including external beam radiotherapy (EBRT), stereotactic radiosurgery (SRS), and fractionated stereotactic radiotherapy (FSRT).
Appendix
Available only for authorised users
Literature
1.
go back to reference Ohguri T, Imada H, Kohshi K, Kakeda S, Ohnari N, Morioka T, Nakano K, Konda N, Korogi Y: Effect of prophylactic hyperbaric oxygen treatment for radiation-induced brain injury after stereotactic radiosurgery of brain metastases. Int J Radiat Oncol Biol Phys 2007, 67: 248–255. 10.1016/j.ijrobp.2006.08.009CrossRefPubMed Ohguri T, Imada H, Kohshi K, Kakeda S, Ohnari N, Morioka T, Nakano K, Konda N, Korogi Y: Effect of prophylactic hyperbaric oxygen treatment for radiation-induced brain injury after stereotactic radiosurgery of brain metastases. Int J Radiat Oncol Biol Phys 2007, 67: 248–255. 10.1016/j.ijrobp.2006.08.009CrossRefPubMed
2.
go back to reference McPherson CM, Warnick RE: Results of contemporary surgical management of radiation necrosis using frameless stereotaxis and intraoperative magnetic resonance imaging. J Neurooncol 2004, 68: 41–47.CrossRefPubMed McPherson CM, Warnick RE: Results of contemporary surgical management of radiation necrosis using frameless stereotaxis and intraoperative magnetic resonance imaging. J Neurooncol 2004, 68: 41–47.CrossRefPubMed
3.
go back to reference Gonzalez J, Kumar AJ, Conrad CA, Levin VA: Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007, 67: 323–326. 10.1016/j.ijrobp.2006.10.010CrossRefPubMed Gonzalez J, Kumar AJ, Conrad CA, Levin VA: Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007, 67: 323–326. 10.1016/j.ijrobp.2006.10.010CrossRefPubMed
4.
go back to reference Torcuator R, Zuniga R, Mohan YS, Rock J, Doyle T, Anderson J, Gutierrez J, Ryu S, Jain R, Rosenblum M, Mikkelsen T: Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol 2009, 94: 63–68. 10.1007/s11060-009-9801-zCrossRefPubMed Torcuator R, Zuniga R, Mohan YS, Rock J, Doyle T, Anderson J, Gutierrez J, Ryu S, Jain R, Rosenblum M, Mikkelsen T: Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol 2009, 94: 63–68. 10.1007/s11060-009-9801-zCrossRefPubMed
5.
go back to reference Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Prabhu S, Loghin M, Gilbert MR, Jackson EF: Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011, 79: 1487–1495. 10.1016/j.ijrobp.2009.12.061PubMedCentralCrossRefPubMed Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Prabhu S, Loghin M, Gilbert MR, Jackson EF: Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011, 79: 1487–1495. 10.1016/j.ijrobp.2009.12.061PubMedCentralCrossRefPubMed
6.
go back to reference Wong ET, Huberman M, Lu XQ, Mahadevan A: Bevacizumab reverses cerebral radiation necrosis. J Clin Oncol 2008, 26: 5649–5650. 10.1200/JCO.2008.19.1866CrossRefPubMed Wong ET, Huberman M, Lu XQ, Mahadevan A: Bevacizumab reverses cerebral radiation necrosis. J Clin Oncol 2008, 26: 5649–5650. 10.1200/JCO.2008.19.1866CrossRefPubMed
7.
go back to reference Jeyaretna DS, Curry WT Jr, Batchelor TT, Stemmer-Rachamimov A, Plotkin SR: Exacerbation of cerebral radiation necrosis by bevacizumab. J Clin Oncol 2011, 29: e159-e162. 10.1200/JCO.2010.31.4815CrossRefPubMed Jeyaretna DS, Curry WT Jr, Batchelor TT, Stemmer-Rachamimov A, Plotkin SR: Exacerbation of cerebral radiation necrosis by bevacizumab. J Clin Oncol 2011, 29: e159-e162. 10.1200/JCO.2010.31.4815CrossRefPubMed
8.
go back to reference Kim JH, Chung YG, Kim CY, Kim HK, Lee HK: Upregulation of VEGF and FGF2 in normal rat brain after experimental intraoperative radiation therapy. J Korean Med Sci 2004, 19: 879–886. 10.3346/jkms.2004.19.6.879PubMedCentralCrossRefPubMed Kim JH, Chung YG, Kim CY, Kim HK, Lee HK: Upregulation of VEGF and FGF2 in normal rat brain after experimental intraoperative radiation therapy. J Korean Med Sci 2004, 19: 879–886. 10.3346/jkms.2004.19.6.879PubMedCentralCrossRefPubMed
9.
go back to reference Dvorak HF, Sioussat TM, Brown LF, Berse B, Nagy JA, Sotrel A, Manseau EJ, Van de Water L, Senger DR: Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 1991, 174: 1275–1278. 10.1084/jem.174.5.1275CrossRefPubMed Dvorak HF, Sioussat TM, Brown LF, Berse B, Nagy JA, Sotrel A, Manseau EJ, Van de Water L, Senger DR: Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 1991, 174: 1275–1278. 10.1084/jem.174.5.1275CrossRefPubMed
10.
go back to reference Nordal RA, Nagy A, Pintilie M, Wong CS: Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: a role for vascular endothelial growth factor. Clin Cancer Res 2004, 10: 3342–3353. 10.1158/1078-0432.CCR-03-0426CrossRefPubMed Nordal RA, Nagy A, Pintilie M, Wong CS: Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: a role for vascular endothelial growth factor. Clin Cancer Res 2004, 10: 3342–3353. 10.1158/1078-0432.CCR-03-0426CrossRefPubMed
11.
go back to reference Li YQ, Ballinger JR, Nordal RA, Su ZF, Wong CS: Hypoxia in radiation-induced blood-spinal cord barrier breakdown. Cancer Res 2001, 61: 3348–3354.PubMed Li YQ, Ballinger JR, Nordal RA, Su ZF, Wong CS: Hypoxia in radiation-induced blood-spinal cord barrier breakdown. Cancer Res 2001, 61: 3348–3354.PubMed
12.
go back to reference Rock JP, Hearshen D, Scarpace L, Croteau D, Gutierrez J, Fisher JL, Rosenblum ML, Mikkelsen T: Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Neurosurgery 2002, 51: 912–919. discussion 919–920PubMed Rock JP, Hearshen D, Scarpace L, Croteau D, Gutierrez J, Fisher JL, Rosenblum ML, Mikkelsen T: Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Neurosurgery 2002, 51: 912–919. discussion 919–920PubMed
13.
go back to reference Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990, 8: 1277–1280.PubMed Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990, 8: 1277–1280.PubMed
14.
go back to reference Sanborn MR, Danish SF, Rosenfeld MR, O'Rourke D, Lee JY: Treatment of steroid refractory, Gamma Knife related radiation necrosis with bevacizumab: case report and review of the literature. Clin Neurol Neurosurg 2011, 113: 798–802. 10.1016/j.clineuro.2011.08.007CrossRefPubMed Sanborn MR, Danish SF, Rosenfeld MR, O'Rourke D, Lee JY: Treatment of steroid refractory, Gamma Knife related radiation necrosis with bevacizumab: case report and review of the literature. Clin Neurol Neurosurg 2011, 113: 798–802. 10.1016/j.clineuro.2011.08.007CrossRefPubMed
15.
go back to reference Furuse M, Kawabata S, Kuroiwa T, Miyatake S: Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases. J Neurooncol 2011, 102: 471–475. 10.1007/s11060-010-0333-3CrossRefPubMed Furuse M, Kawabata S, Kuroiwa T, Miyatake S: Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases. J Neurooncol 2011, 102: 471–475. 10.1007/s11060-010-0333-3CrossRefPubMed
Metadata
Title
Reversal of cerebral radiation necrosis with bevacizumab treatment in 17 Chinese patients
Authors
Yang Wang
Li Pan
Xiaofang Sheng
Yin Mao
Yu Yao
Enmin Wang
Nan Zhang
Jiazhong Dai
Publication date
01-12-2012
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2012
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/2047-783X-17-25

Other articles of this Issue 1/2012

European Journal of Medical Research 1/2012 Go to the issue